Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.39 | N/A | -473.53% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.39 | N/A | -473.53% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current market conditions affecting performance. They highlighted a focus on operational improvements but did not provide specific future guidance.
Management acknowledged challenges in meeting earnings expectations.
They emphasized ongoing efforts to improve operational efficiency.
There was no specific guidance provided for future performance.
Veracyte's earnings report showed a significant miss on EPS, which contributed to a slight decline in stock price. The lack of revenue figures and forward guidance raises uncertainty about the company's near-term performance. Investors may be cautious as management addresses operational challenges without clear expectations for recovery.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HOME DEPOT INC
Feb 20, 2024